BioPharma Resources

Drug Trial Radar · NCT07720193

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

A Randomized, Double-blind, Placebo-controlled, Phase III Trial of LBL-024 Combined With Platinum-based Chemotherapy as First-line Treatment of Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Dec 22, 2030

Study completion Dec 22, 2030

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.

Conditions

  • Advanced Extrapulmonary Neuroendocrine Carcinoma

Interventions

  • LBL-024 for InjectionDrug

    Intravenous infusion

  • Etoposide injectionDrug

    Intravenous infusion

  • Cisplatin injectionDrug

    Intravenous infusion

  • Carboplatin injectionDrug

    Intravenous infusion

  • LBL-024 placebo for injectionDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Cancer Hospital

    Lanzhou, Gansu, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital and Institute

    Shengyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.